EGRX - Eagle Pharmaceuticals EPS misses by $0.49 misses on revenue
Eagle Pharmaceuticals (EGRX): Q1 Non-GAAP EPS of $0.24 misses by $0.49; GAAP EPS of -$0.03 misses by $0.23.Revenue of $41.25M (-10.4% Y/Y) misses by $3.78M.2021 Expense GuidanceR&D spend in 2021, on a non-GAAP basis, is expected to be $26-$30 million, as compared to $27.8 million in 2020.SG&A spend in 2021, on a non-GAAP basis, is expected to be $52-$56 million, as compared to $50.9 million in 2020. This represents a reduction from earlier guidance for 2021 SG&A spend of $56-60 million.Press Release
For further details see:
Eagle Pharmaceuticals EPS misses by $0.49, misses on revenue